Ms. Iris Bincovich reports

INNOCAN PHARMA ANNOUNCES LAUNCH OF CBD VETERINARY COMMERCIALIZATION TEAM

Innocan Pharma Corp. has launched its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.

Innocan chief executive officer Iris Bincovich stated: "We are excited to announce the appointment of a dedicated internal team covering the financial, scientific and legal aspects required to engage with prospective clients in the veterinary field. Our goal is to commercialize, partner and/or sell Innocan's intellectual property portfolio to veterinary indications. We believe there is significant potential in the veterinary market for our CBD-based products."

CBD has been shown to have a wide range of therapeutic properties, including anti-inflammatory, analgesic and anti-anxiety effects. The veterinary market is an important sector that can benefit from the potential therapeutic effects of CBD. The appointment of a dedicated internal team will foster engagement between Innocan and prospective clients in the veterinary field in order to explore potential collaborations and commercialization opportunities.

Innocan's innovative CBD-based products have previously demonstrated promise in human clinical trials, and the company is eager to explore the potential for these products in the veterinary field. The company believes that the veterinary market represents a significant opportunity for growth, and it looks forward to working with potential collaborators to bring these products to market.

About Innocan Pharma Corp.

Innocan is a pharmaceutical technology company that operates under two main segments: pharmaceuticals and consumer wellness. In the pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies, combined with cannabinoid science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the bloodstream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the central nervous system (CNS). In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative and high performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted on-line sales.

We seek Safe Harbor.